Artificial Intelligence in Drug Discovery and Development (AI‑DD) leverages advanced algorithms, machine learning, and data analytics to accelerate target identification, lead optimization, and clinical trial design, fundamentally reshaping pharmaceutical R&D. The relevance of AI‑DD lies in its ability to slash discovery timelines, reduce costs, and enhance success rates for novel therapeutics. Artificial Intelligence in Drug Discovery and Development market size reached approximately $2.3 billion in 2025, and the growth outlook projects a compound annual growth rate (CAGR) of about 21.5% through 2033, driving the market forecast toward an estimated $7.8 billion by 2033. This expansion is propelled by macro drivers such as exploding biomedical data volumes, heightened demand for personalized medicine, and supportive regulatory frameworks that encourage AI‑enabled innovation. Key forces shaping the industry include rapid technology shifts toward deep learning and natural language processing, intensifying competition among pharma giants and biotech start‑ups, and evolving data‑privacy regulations that dictate how patient‑derived datasets can be leveraged.